서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 17 of 17

Issue DateTitle / Author(s) / CitationFileAltmetrics
2016-03
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
DOI
2016-04
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
DOI
2016-11
Palbociclib and Letrozole in Advanced Breast Cancer
DOI
2017-09
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
DOI
2018-07
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
DOI
2018-09
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies
DOI
2018-11
Overall survival with palbociclib and fulvestrant in advanced breast cancer
DOI
2019-07
Overall survival with ribociclib plus endocrine therapy in breast cancer
DOI
2020-01
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
DOI
2020-02
Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))
DOI
2021-04
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
DOI
2021-08
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
DOI
2022-02
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
DOI
2022-03
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
DOI
2022-07
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
DOI
2022-08
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
DOI
2023-12
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
DOI
1